NCT03188276 is a EARLY_PHASE1 clinical trial of Ledipasvir-Sofosbuvir in Chronic Hepatitis C, sponsored by Third Affiliated Hospital, Sun Yat-Sen University.

Who is sponsoring NCT03188276?

NCT03188276 is sponsored by Third Affiliated Hospital, Sun Yat-Sen University.

What drugs are being tested in NCT03188276?

Interventions in NCT03188276: Ledipasvir-Sofosbuvir, Daclatasvir-Sofosbuvir.

What condition does NCT03188276 study?

NCT03188276 studies Chronic Hepatitis C.

Is NCT03188276 still recruiting?

NCT03188276 is currently completed. Last updated 15 June 2017.

Last reviewed 2017-06-15 · How we verify

NCT03188276

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs

Completed EARLY_PHASE1 Last updated 15 June 2017

What this trial tests

EARLY_PHASE1 trial testing Ledipasvir-Sofosbuvir in Chronic Hepatitis C in 52 participants. Completed in 1 May 2017.

Timeline

1 February 2016

Primary endpoint
1 May 2017

1 May 2017

Quick facts

Lead sponsor	Third Affiliated Hospital, Sun Yat-Sen University
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	52
Start date	1 February 2016
Primary completion	1 May 2017
Estimated completion	1 May 2017

Drugs / interventions tested

Ledipasvir-Sofosbuvir
Daclatasvir-Sofosbuvir

Conditions studied

Chronic Hepatitis C — all drugs for Chronic Hepatitis C →

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University

Who can join

Adults 18 to 76, any sex, with Chronic Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hepatitis C virus (HCV) infection is easy to chronic and can progress to cirrhosis and liver cancer. Direct-acting antiviral treatment can significantly improve the prognosis of the disease and the efficacy is seemingly not affected by a variety of viral factors. In addition, direct-acting antiviral agents therapy may affect the transformation of the immune cells and ameliorate the host immune status consequently. This study mainly investigated the relationship between Direct Acting Antiviral Treatment effect and the functional activity of myeloid-derived suppressor cells (MDSCs) and natural killer cells (NK cells) in Chronic Hepatitis C.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Roles of Myeloid-Derived Suppressor Cells in Liver Disease.
Zhang C, Sui Y, Liu S, Yang M. · · 2024 · cited 2× · PMID 38397901 · DOI 10.3390/biomedicines12020299

Verify or expand the search:

Other trials of Ledipasvir-Sofosbuvir

Trials testing the same drug.

NCT03063723 — Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs · completed

Other recruiting trials for Chronic Hepatitis C

Currently open trials in the same condition.

NCT06180590 — The Efficacy of Vosevi in Treating DAA-experienced Patients · recruiting
NCT03993925 — Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong · active not recruiting

Other Third Affiliated Hospital, Sun Yat-Sen University trials

Trials by the same sponsor.

NCT07409259 — PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure · EARLY_PHASE1 · active not recruiting
NCT07281664 — Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hep · NA · not yet recruiting
NCT07338552 — Effectiveness of a Virtual Health Management Community (VHMC) for Pre-diabetes in China · NA · not yet recruiting
NCT07354997 — Establishing a Virtual Health Community Management Model for Pre-Diabetes Patients · NA · completed
NCT07253233 — Treatment of Spinal Cord Injury Using Autologous Concentrated Growth Factors · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03188276 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Third Affiliated Hospital, Sun Yat-Sen University
Last refreshed: 15 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03188276.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing